logo
Plus   Neg
Share
Email

Alnylam, Dicerna Form RNAi Therapeutics Collaboration For Alpha-1 Liver Disease

Alnylam Pharmaceuticals, Inc. (ALNY) and Dicerna Pharmaceuticals, Inc. (DRNA) said Monday they have formed a development and commercialization collaboration on investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin or A1AT deficiency-associated liver disease (alpha-1 liver disease).

In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam's lumasiran and Dicerna's nedosiran investigational programs to treat primary hyperoxaluria or PH.

The companies expect these agreements will enhance and accelerate their ability to bring these orphan product candidates to market.

Under the development and commercialization agreement, Alnylam's ALN-AAT02 and Dicerna's DCR-A1AT, two investigational RNAi therapeutics that are in Phase 1/2 development, will be explored for the treatment of alpha-1 liver disease.

Under the agreement, Dicerna will assume responsibility for both ALN-AAT02 and DCR-A1AT at its cost, and may progress one or both of these investigational medicines through clinical development.

Dicerna will select which product candidates to advance in development for the treatment of patients with alpha-1 liver disease. At Phase 3 completion, Alnylam has the no-cost opportunity to opt-in to commercialize the selected candidate in countries outside the U.S., where it already has a commercialization infrastructure in place.

If Alnylam exercises its opt-in right, each party shall pay tiered royalties to the other party based on net product sales generated in its territory at rates dependent on which candidate is commercialized.

If Alnylam waives its commercialization option, Dicerna will retain worldwide rights to commercialize the selected candidates in exchange for milestones and royalties payable to Alnylam. The rate will be dependent on which candidate is ultimately commercialized.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Marriott International reopened all its hotels in China while it sees a recovery in demand in the United States, Chief Executive Officer Arne Sorenson said. The company had closed majority of its hotels in China and across the world following the spread of coronavirus and related lockdowns. The hotel chain, with around 350 outlets across China, said its occupancy rate in the country is now at 40% Many retailers including Target, Walmart and CVS announced temporary store closures in various regions across the United States following violence and looting amid the unrest related to the death of George Floyd. The street protests, some peaceful and some violent, erupted across the nation after Floyd was mercilessly killed by Minnesota police. Nestle USA, a division of Swiss food major Nestlé, announced the recall of certain Lean Cuisine Fettuccini Alfredo products citing misbranding and the presence of an undeclared allergen. According to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS, the recall involves approximately 29,002 pounds of chicken products.
Follow RTT